Compare Lowe`s Companies Inc (LOW) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Lowe`s Companies Inc vs Summit Therapeutics Inc — how do they compare? Lowe`s Companies Inc trades at $216.56 (market cap $124.06B), while Summit Therapeutics Inc trades at $15.23 (market cap $12.06B). The key difference: Lowe`s Companies Inc is far larger — about 10.3× Summit Therapeutics Inc's market cap, and Lowe`s Companies Inc pays a 2.26% dividend while Summit Therapeutics Inc pays none. Which is the better fit depends on your goals.
| LOW | SMMT | |
|---|---|---|
Market Cap | $124.06B | $12.06B |
Sector | Consumer Cyclical | Health |
52-Week High | $287.39 | $26.98 |
52-Week Low | $201.92 | $12.55 |
Enterprise Value | $165.81B | $11.39B |
Dividend Yield | 2.26% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Lowe's (LOW) trades at $216.14, down 1.23% with a bullish technical outlook supported by moving averages. The company maintains solid fundamentals with consistent earnings beats and a 7.51% net margin, though revenue declined to $83.67B in 2025. Analyst consensus remains strongly positive with a $257.06 price target and 61% buy ratings. Recent news highlights upcoming Q2 2026 earnings and community investments.
LOW presents a compelling investment case with strong analyst support and stable cash flows, but faces risks from competitive pressures and declining revenue trends. The stock's current valuation at 18.7x P/E appears reasonable given earnings consistency, though investors should monitor same-store sales performance in the upcoming earnings report.
Summit Therapeutics (SMMT) trades at $15.23, up 2.42% today, with a bullish technical signal and strong analyst consensus. The stock shows mixed earnings performance but benefits from positive news on ivonescimab's regulatory progress and clinical expansions. Despite negative profitability metrics, investor sentiment is buoyed by a high price target of $38.00 and recent partnership announcements in cancer drug development.
Outlook hinges on FDA approval for ivonescimab by November 2026, offering significant upside if successful. Risks include cash burn, ongoing losses, and fiduciary investigations. The stock presents a high-risk, high-reward opportunity for speculative investors betting on clinical successes.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Lowe`s Companies Inc
Lowe's is the second-largest home improvement retailer in the world, operating 1,969 stores and servicing around 230 dealer-owned stores throughout the United States and Canada. The firm's stores offer products and services for home decorating, maintenance, repair, and remodeling, with maintenance and repair accounting for two thirds of products sold. Lowe's targets retail do-it-yourself (around 75% of sales) and do-it-for-me customers as well as commercial and professional business clients (around 25% of sales). We estimate Lowe's captures a low-double-digit share of the domestic home improvement market, based on U.S. Census data and management's estimates for market size.
Read more on LOW →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
